JP2024538839A5 - - Google Patents
Info
- Publication number
- JP2024538839A5 JP2024538839A5 JP2024529656A JP2024529656A JP2024538839A5 JP 2024538839 A5 JP2024538839 A5 JP 2024538839A5 JP 2024529656 A JP2024529656 A JP 2024529656A JP 2024529656 A JP2024529656 A JP 2024529656A JP 2024538839 A5 JP2024538839 A5 JP 2024538839A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- composition according
- cells
- composition
- mesenchymal progenitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021903706 | 2021-11-17 | ||
| AU2021903706A AU2021903706A0 (en) | 2021-11-17 | Method of treating progressive heart failure in subjects at high risk of poor outcomes | |
| US202263384200P | 2022-11-17 | 2022-11-17 | |
| PCT/US2022/080089 WO2023092043A1 (en) | 2021-11-17 | 2022-11-17 | Method of treating progressive heart failure in subjects at high risk of poor outcomes |
| US63/384,200 | 2022-11-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538839A JP2024538839A (ja) | 2024-10-23 |
| JP2024538839A5 true JP2024538839A5 (cg-RX-API-DMAC7.html) | 2025-11-28 |
Family
ID=84767093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529656A Pending JP2024538839A (ja) | 2021-11-17 | 2022-11-17 | 転帰不良のリスクが高い対象における進行性心不全の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250090589A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024538839A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240115826A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022394471A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3238314A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023092043A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12702683B2 (en) | 2019-01-03 | 2026-08-11 | Mesoblast International Sárl | Method for improving visual acuity |
| WO2021176001A1 (en) | 2020-03-05 | 2021-09-10 | Mesoblast International Sàrl | Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US6251295B1 (en) | 1998-01-08 | 2001-06-26 | Nexell Therapeutics Inc. | Method for recirculation washing of blood cells |
| CA3247653A1 (en) * | 2014-12-23 | 2025-10-31 | Mesoblast International Sarl | Method for treating heart failure |
-
2022
- 2022-11-17 AU AU2022394471A patent/AU2022394471A1/en active Pending
- 2022-11-17 JP JP2024529656A patent/JP2024538839A/ja active Pending
- 2022-11-17 US US18/711,167 patent/US20250090589A1/en active Pending
- 2022-11-17 WO PCT/US2022/080089 patent/WO2023092043A1/en not_active Ceased
- 2022-11-17 KR KR1020247018462A patent/KR20240115826A/ko active Pending
- 2022-11-17 CA CA3238314A patent/CA3238314A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024500698A5 (cg-RX-API-DMAC7.html) | ||
| Zhang et al. | A collagen hydrogel loaded with HDAC7-derived peptide promotes the regeneration of infarcted myocardium with functional improvement in a rodent model | |
| Ohnishi et al. | Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis | |
| Aguilar et al. | New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation | |
| US9226978B2 (en) | Method of treating ischemic disorders | |
| US20120014920A1 (en) | Annexin and its use to treat inflammatory disorders | |
| He et al. | Activation mechanisms and multifaceted effects of mast cells in ischemia reperfusion injury | |
| Beiert et al. | Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties | |
| JP2018538367A (ja) | ホルミルペプチド受容体2/リポキシンa4受容体(fpr2/alx)の心臓疾患を治療するための標的設定 | |
| JP2023529502A5 (cg-RX-API-DMAC7.html) | ||
| Wang et al. | The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives | |
| Roubille et al. | What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials | |
| Nakamura et al. | The effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction | |
| Zisa et al. | Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair | |
| Sun et al. | Modified bFGF targeting connective tissue growth factor in the injured microenvironment improved cardiac repair after chronic myocardial ischemia | |
| US9974831B2 (en) | Methods of reducing myocardial injury following myocardial infarction | |
| WO2005049062A1 (en) | Use of g-csf for treating ischemia | |
| Rosenberg et al. | Rapid progressive eosinophilic cardiomyopathy in a patient with Churg–Strauss syndrome (CSS) | |
| Orabi et al. | Molecular and clinical roles of incretin-based drugs in patients with heart failure | |
| Damayanti et al. | Mesenchymal Stem Cells Role in COVID-19 Myocardial Injury | |
| Baka et al. | Ivabradine in the management of COVID-19-related cardiovascular complications: a perspective | |
| JP2023170339A (ja) | 拡張型心筋症を処置または予防するための医薬組成物 | |
| Karaman et al. | Torsade de Pointes Following Myocarditis; A Case Report | |
| Wang et al. | Severe Myocarditis Caused by XELOX Chemotherapy After Rectal Cancer Surgery: A Case Report | |
| Horio et al. | Bio-molecular markers for cardiovascular disease: significance of natriuretic peptides and adrenomedullin |